|
| Tofacitinib Impurity K Basic information |
Product Name: | Tofacitinib Impurity K | Synonyms: | Azilsartan medoxomil impurity332;3-((3R,4R)-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanoic acid (Tofacitinib Impurity);1-Piperidinepropanoic acid, 4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-, (3R,4R)- | CAS: | 2328165-36-0 | MF: | C16H21N5O3 | MW: | 331.38 | EINECS: | | Product Categories: | | Mol File: | 2328165-36-0.mol | |
| Tofacitinib Impurity K Chemical Properties |
density | 1.367±0.06 g/cm3(Predicted) | solubility | DMSO (Slightly), Methanol (Slightly) | form | Solid | pka | 4.96±0.32(Predicted) | color | White to Off-White |
| Tofacitinib Impurity K Usage And Synthesis |
Uses | 3-((3R,4R)-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanoic Acid is an impurity of Tofacitinib (T528000), an enantiopure stereoisomer of the drug, Janus kinase 3(Jak3) inhibitor (CP-690,550) that has been found to inhibit selected members of the STE7 and STE20 subfamily of kinases. |
| Tofacitinib Impurity K Preparation Products And Raw materials |
|